相关实验视频
Updated: Aug 17, 2026

Cecal Ligation Puncture Procedure
Published on: May 7, 2011
败血症或败血性休克患者的Levosimendan与死亡率之间的关联:系统性审查和元分析
Zengzheng Ge1, Yanxia Gao2, Xin Lu1
1Emergency Department, State Key Laboratory for Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing.
莱沃西门丹并没有降低败血症或败血性休克患者的28天死亡率. 虽然心脏功能和乳酸盐水平有所改善,但不良反应更频繁,死亡率相似.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 莱沃西门丹越来越多地用于败血症和败血症休克,以改善器官功能并降低死亡率.
- 这一元分析评估了levosimendan在降低这些重症患者的死亡率方面的疗效.
结论:
- 莱沃西门丹与28天死亡率降低或在性休克患者中改善SOFA得分无关.
- 该药物在改善心脏功能和降低血清乳酸盐水平方面具有显著的益处.
- 增加的不良反应需要仔细考虑levosimendan在败血症休克管理中的风险益处概况.
更多相关视频
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Edema II: Pathophysiology